In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celgene Corp.

www.celgene.com

Latest From Celgene Corp.

Rybelsus, Other Treatment Improvements For Chronic Disease Have OptumRx’s Attention

UnitedHealthcare’s pharmacy benefit manager highlights potential cost pressures from upcoming novel or improved treatments for diabetes, wet AMD, HIV and migraine, as well as luspatercept for beta thalassemia, in its latest pipeline report.

Pricing Strategies Reimbursement

Orphan AML Products Face CHMP Questioning

Companies developing new AML treatments are among those being called before the European Medicines Agency this week for questioning over marketing applications approaching the end of the review process. 

Europe Drug Review

Acceleron Ends ACE-083 FSHD Testing After Phase II Failure

Acceleron ended testing of ACE-083 in facioscapulohumeral muscular dystrophy after the investigational drug missed Phase II endpoints.

Neurology Clinical Trials

Biopharma Quarterly Dealmaking Statistics, Q2 2019

Biopharma companies raised $12.4bn in Q2, largely from follow-on public offerings. In the latest mega-merger of the year, AbbVie spent $63bn on Allergan and its established portfolio. Many of the higher-valued alliances focused on the area of protein degradation.

Market Intelligence Deals
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register